Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification.

Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. · 2016

Read Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. by Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4824831.txt.

Introduction

Kazuhiro Yoshida and four co-authors propose a new sorting for advanced stomach cancer in Gastric Cancer in 2016. Some stage IV cancers, spread beyond the stomach, can still be cut out after chemotherapy shrinks them, a strategy called conversion therapy. Which patients qualify has been guesswork, so the authors sort stage IV disease by its biology into four categories.

The split turns on spread into the belly lining, which behaves differently from spread through the blood. Categories range from spread that is removable at once to spread across belly and organs that no surgery can cure. Conversion surgery, they propose, fits mainly the second category, some of the third, and almost none of the fourth, where care should lead. Expected survival follows the same order.

Catalog record

CREATORYoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4824831

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification By Kazuhiro Yoshida, Kazuya Yamaguchi, Naoki Okumura, Toshiyuki Tanahashi, Yasuhiro Kodera Published in: Gastric Cancer DOI: 10.1007/s10120-015-0575-z ABSTRACT Conversion therapy for gastric cancer (GC) has been the subject of much recent attention. It is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors that were originally unresectable or marginally resectable for technical and/or oncological reasons. However, the indications for resection remain to be clarified. In the present review, we focus on the biology and heterogeneous characteristics of stage IV GC and propose new categories of classification. Stage IV GC patients can be divided based on the absence (categories 1 and 2) or presence (categories 3 and 4) of macroscopically detectable peritoneal dissemination, which has a different biological outcome compared to hematological metastasis. Category 1 is defined oncologically as stage IV but the metastasis is technically resectable. Category 2 includes a marginally resectable metastasis or patients for whom the operation would not necessarily be the best choice. Category 3 includes a potentially unresectable metastasis of peritoneal dissemination that is only macroscopically detectable. Category 4 includes noncurable metastasis with peritoneal and other organ metastasis. The indications for conversion therapy might include the patients from category 2, some patients from category 3 and a very small number of patients from category 4. The longer survival can be expected for patients corresponding to categories 1, 2 and, to a lesser extent, 3, while the treatment of other patients focuses on “care.” The provision of conversion therapy for stage IV GC patients might be one of the main roles of surgical oncologists in the near future. INTRODUCTION In spite of early diagnosis and improved intensive treatments, GC remains the second leading cause of death throughout the world [1]. With the development of therapeutic approaches, the standard treatment of GC has been established, as is demonstrated in the Japanese treatment guidelines for GC [2]. Treatments include ESD in T1a tumors, laparoscopic surgery or, to a lesser extent, lymphadenectomy in T1b tumors and standard D2 lymphadenectomy for locally advanced resectable gastric cancer. As for metastatic and recurrent GC, several new regimens have been developed that improve patient survival [3–7]. However, the median survival time (MST) remains at only 13–16 months. In order to further improve the survival of stage IV GC patients, new therapeutic approaches should be considered [8, 9]. On the other hand, recent improvements in the survival of metastatic colorectal cancer patients have mainly depended on new cytotoxic and molecular target agents (FOLFOX, FOLFIRI, XELOX and SOX with bevacizumab, cetuximab, panitumab, regorafinib and ramcirumab), which have recently achieved an increase in MST from 6 to 30 months [10–17]. Moreover, the surgical approach to metastatic lesions designated for conversion therapy or an oncosurgical approach has played a very crucial role in the prolonged survival of metastatic colorectal patients [18–20] because this operation, which aims at R0 resection, might be able to cure patients with metastatic lesions for whom the major treatment would previously have been chemotherapy. Although the prognosis of stage IV GC has recently improved as the result of new chemotherapeutic and molecular targeting agents, it remains unsatisfactory. With the development and improved response of the chemotherapy regimens, a number of conversion therapy approaches have been successfully demonstrated in stage IV GC [21–26]. However, significant aspects of these approaches, such as the indications, chemotherapy regimens and timing of the operation, remain to be clarified. In the present review, current developments in the treatment of stage IV GC will be discussed, conversion therapy will be defined and new categories of classification for stage IV GC will be proposed. THE HISTORY OF METASTATIC GC CLINICAL TRIALS IN JAPAN According to the updated Japanese guidelines on gastric cancer [27], S-1 plus cisplatin (S-1/CDDP) is regarded as the first-line chemotherapy and is the first-level recommendation in HER 2-negative patients. The capecitabine plus cisplatin (XP) regimen and S-1 plus docetaxel (S-1/docetaxel) are also nominated as the second-level recommendations. On the other hand, in HER 2-positive patients, trastuzumab + XP is regarded as the recommended treatment regimen [7]. This consensus has been established on the basis of the history of clinical trials (Fig. 1), and the results of trials in Japan are summarized in Table 1. Trials in Western countries are also summarized in Table 2.Fig. 1The history of metastatic GC clinical trials in JapanTable 1Involvement of non-measurable lesions in Japanese clinical trialsTrial [Ref no.]TreatmentResponse rate (%)Median overall survival (M)Frequency of non-measurable lesionsTotal populationMeasurableNon-measurable(%)TotalJCO9912 [28]5-FU910.8N/AN/A37.2 % (87/234)33.0 % (232/704)CPT-CDDP3812.332.2 % (76/236)S-12811.429.4 % (69/234)SPIRITS [3]S-13111.0N/AN/A24 % (36/150)29.2 % (87/298)S-1/CDDP5413.034 % (51/148)TOP-002 [29]S-126.910.5N/AN/AN/A33.3 % (105/315)S-1/CPT41.512.8N/ASTART [5]S-126.810.810.312.040.8 % (131/321)39.3 % (250/635S-1/DTX38.812.511.717.937.9 % (119/314)SOS [30]SP55013.9N/AN/A37 % (113/309)N/ASP36014.139 % (120/306)G-SOX [31]SP52.213.1N/AN/A19.8 % (64/324)19.5 % (125/642)SOX55.714.119.2 % (25/294)ToGA [7]XP3511.1N/AN/A11.3 % (33/290)9.9 % (58/584)XP + Tmab4713.88.5 % (25/294)AVAGAST [32]XP37.410.1N/AN/A23.2 % (90/387)21.4 % (166/774)XP + Bev46.012.119.6 % (76/387)Table 2Involvement of non-measurable lesions clinical trials of Western countriesTrial [Ref no.]TreatmentResponse rate (%)Median overall survival (M)Frequency of non-measurable lesionsTotal populationMeasurableNon-measurable(%)TotalEORTC [37]FAMTX126.7N/AN/A12.3 % (16/130)12.8 % (50/390)ELF97.214.8 % (19/128)FUP207.211.4 % (15/132)FLAGS [38]CF31.97.9N/AN/A4.3 % (22/508)4.2 % (43/1029)CS29.18.64.0 % (21/521)V325 [39]CF258.6N/AN/AN/AN/ADCF379.2N/ACF versus IF [40]CF25.88.7N/AN/A25.2 % (41/163)24.3 % (81/333)IF31.89.023.5 % (40/170)REAL-2 [41]ECF40.79.9N/AN/AN/AN/AECX46.49.9N/AEOF42.49.3N/AEOX47.911.2N/AML17032 [42]FP329.3N/AN/A18.6 % (29/156)18.7 % (59/316)XP4610.518.8 % (30/160) JCOG9912 [28] was the first pivotal trial to compare 5FU versus S-1 versus CPT11 plus cisplatin (CPT/CDDP) in Japan; however, it did not demonstrate the superiority of CPT/CDDP. As a result, S-1 was regarded as the standard regimen. S-1/CDDP was compared to S-1 monotherapy in the SPIRITS trial [3], which demonstrated the combination of cisplatin (60 mg/m2 for 8 days) with S-1 for 3 weeks on and 2-weeks off. The treatment was repeated every 5 weeks, unless disease progression was observed. The MST for S-1/CDDP and S-1 was 13.0 and 11.0 months, respectively, and the superiority of S-1/CDDP was demonstrated. A randomized phase III trial (TOP 002) was conducted to evaluate the safety and efficacy of IRIS (S-1/CPT-11) versus S-1 for advanced gastric cancer, which could not demonstrate a significant difference in patient survival [29]. The START trial was a randomized phase III study comparing S-1 alone with the S-1/docetaxel combination through the JACCRO GC03 trial [5]. This study was a prospective, multicenter, multinational (Korea and Japan), randomized, phase III study of patients with AGC. Docetaxel (40 mg/m2 on day 1) was administered with S-1 (80 mg/m2/day) for 2 weeks on and 1 week off. The MST for S-1/docetaxel and S-1 was 12.5 and 10.8 months, respectively, and the HR was 0.837 (95 % CI 0.711–0.985; P = 0.0319), showing the significant superiority of the doublet regimen. Moreover, in the patients with non-measurable lesions, MST for S-1/docetaxel and S-1 was 17.9 and 12.0 months, respectively. A prospective randomized control trial of adjuvant therapy for stage III GC is currently being conducted to compare S-1/docetaxel versus S-1 monotherapy as a control arm. On the other hand, as a modification of the 5-weekly S-1/CDDP regimen, the SOS trial demonstrated that the triweekly S-1/CDDP regimen has the same efficacy as the original schedule. In order to reduce the renal toxicity, oxaliplatin was used to replace cisplatin [30]. The G-SOX trial demonstrated an equal efficacy with lower toxicity and will be widely administered in general practice [31]. In the

Read the complete text